Contact:Katie Sullivan
Phone:(434)243-7231
E-mail:kls8d@virginia.edu
UVa Health System, Department of Radiation Oncology seeks men and women, age 18 or older, who have been recently diagnosed with esophageal cancer for a research study.
The purpose of this study is to compare the effects, good and/or bad, of radiation therapy and chemotherapy (paclitaxel and cisplatin) with or without the addition of cetuximab to find out which treatment is better. Cetuximab may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. Cetuximab is FDA approved for the treatment of colorectal and head and neck cancers but is experimental for esophageal cancer. Cetuximab is investigational in this study.
This is a randomized study.
All patients will receive chemotherapy with paclitaxel and cisplatin. Participants will have an equal chance of being registered to one of the two following groups:
Group 1: If you are randomized into Group 1 you will receive cetuximab in addition to radiation therapy and paclitaxel plus cisplatin.
Group 2: If you are randomized into Group 2 you will not receive cetuximab. You will be treated with radiation and paclitaxel plus cisplatin only.
You will receive treatment with radiation and drug therapy for approximately 6 weeks. After you are finished the treatment, your study doctor will ask you to visit the office for follow-up exams every 4 months for 2 years, every 6 months for 2 years, and then every year indefinitely.
No compensation is provided for this study.
Contact Information:
For more information please contact:
" Katie L. Sullivan, MSW, CCRC
" 434-243-7231, kls8d@virginia.edu
" Insert IRB-HSR # 14034
Principal Investigator: Tyvin Rich, MD
|
|
Primary Investigator: Rich Tyvin, A